Salute e Benessere

BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and…

Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase, a promising therapeutic target for serious diseases. Pacritinib (marketed as VONJO®) is a JAK2 inhibitor indicated for treatment of myelofibrosis, a bone marrow disorder, and works by blocking certain growth factors and cytokines. Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase, a promising therapeutic target for serious diseases....
PR Newswire
28/05/2024

Metabolon Now Includes Spectral Data Files for All Global Discovery Panel…

"The availability of spectral data enhancement not only provides clients with a more comprehensive view of their metabolomics data but also reinforces our commitment to transparency and delivering unparalleled value to our clients," said Ro Hastie, CEO at Metabolon. "The availability of spectral data enhancement not only provides clients with a more comprehensive view of their metabolomics data but also reinforces our commitment to transparency and delivering unparalleled value to…
PR Newswire
28/05/2024

Calliditas Therapeutics Presents Data at the 61st European Renal Association…

Additionally, the findings of a real-world analysis of challenges associated with the use of systemic glucocorticoids demonstrate significant side effects and costs for IgAN patients treated with systemic glucocorticoids (SGC), such as Prednisone and Prednisolone. Additionally, the findings of a real-world analysis of challenges associated with the use of systemic glucocorticoids demonstrate significant side effects and costs for IgAN patients treated with systemic glucocorticoids (SGC), such...
PR Newswire
28/05/2024

Kinomica, King's College London and King's College Hospital NHS Foundation Trust…

Debashis Sarker MBChB FRCP PhD, Reader in Experimental Oncology, King's College London and Consultant Medical Oncologist at King's College Hospital, part of King's Health Partners, will present the results of the collaboration in a poster titled 'Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC)'. Debashis Sarker MBChB FRCP PhD, Reader in Experimental Oncology, King's College...
PR Newswire
28/05/2024

Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned…

J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rightsNM26 is a Phase 2-ready bi-specific antibody from Numab's pipeline of candidates, discovered and engineered using its proprietary MATCH™ technology platform HORGEN, Switzerland, May28, 2024(GLOBE NEWSWIRE) -- ...
Nasdaq GlobeNewswire
28/05/2024

Oral Hygiene Product Market to Hit $36.4 Billion Valuation at 4.2% CAGR by 2034…

Food can get lodged in the mouth after each meal, leading to tooth decay and other issues. As a result, more individuals are using dental picks to remove food debris from between their teeth and flossing to eliminate food particles and plaque. Food can get lodged in the mouth after each meal, leading to tooth decay and other issues. As a result, more individuals are using dental picks to remove food debris from between their teeth and flossing to eliminate food particles and plaque. For...
PR Newswire
28/05/2024

Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to…

A New Frontier in Age-Related Therapies A New Frontier in Age-Related Therapies Products resulting from this collaboration will utilize Turn Bio's Epigenetic Reprogramming of Age (ERA TM ) technology and its novel eTurna™ delivery platform. These cutting-edge technologies aim to restore optimal gene expression, combatting the effects of aging at the cellular level to treat and potentially cure chronic conditions. "This partnership is a milestone for Turn Bio," said company CEOAnja...
PR Newswire
28/05/2024

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024Lausanne, Switzerland, May 28, 2023– AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 Global Healthcare Conference,...
Nasdaq GlobeNewswire
28/05/2024

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

DUBLIN, May 28, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston. ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. DUBLIN,May 28, 2024/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today...
PR Newswire
28/05/2024

Outdated perceptions and practices fuelling mental health crisis, new Economist…

International analysis of mental health provision in eight G20 countries reveals stigma, a shortage of mental health professionals and inconsistent availability and quality of care are creating barriers to vital mental health care servicesNew research highlights global and country-level insights into where action is needed alongside recommendations for measures aimed at addressing these challenges London, Tue, 05/28/2024 - Findings from a new Economist Impact health care study...
Nasdaq GlobeNewswire
28/05/2024

Insmed Announces Positive Topline Results from Landmark ASPEN Study of…

—Brensocatib Well-Tolerated at Both Dosage Strengths— —Brensocatib Well-Tolerated at Both Dosage Strengths— —Results fromASPENValidate DPP1 Inhibition as New Mechanism of Action with Potential to Address Range of Neutrophil-Mediated Diseases— —Insmed Plans to Advance Quickly Toward U.S. Regulatory Filing, with Anticipated U.S. Launch in Mid-2025, Pending Approval— —Insmed to Host Investor Call at8:00 am ET on Tuesday, May 28, 2024— BRIDGEWATER, N.J.,May 28, 2024...
PR Newswire
28/05/2024

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May28, 2024(GLOBE NEWSWIRE) --Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:Jefferies Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings on June 5-6 and a...
Nasdaq GlobeNewswire
28/05/2024

Urteste has successfully developed a prototype urine-based diagnostic test for…

28 MAY 2024 PRESS RELEASE Urteste has successfully developed a prototype urine-baseddiagnostictestfordetecting braintumoursGdańsk,Poland–28MAY2024,UrtesteS.A.(WarsawStockExchange:URT)biotechnologycompany specialising in the development of breakthrough technology to detect cancer from urinesampleshasdevelopedaprototypeIVDtestfordetectingbraintumours.Urtestenowhasapipelineof 12 prototype diagnostic tests for the...
Nasdaq GlobeNewswire
28/05/2024

Medical Device Packaging Market worth $54.1 billion by 2029 - Exclusive Report…

Browse in-depth TOC on "Medical Device Packaging Market". Browse in-depth TOC on "Medical Device Packaging Market". 485 – Tables 59 – Figures337– Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=54155604 "Plastic is projected to be the fastest-growing segment in the medical device packaging market." Plastic is the fastest-rising segment for the medical device packaging market from 2024 to 2029, in terms of value. This is because…
PR Newswire
28/05/2024

Spineart Receives 510(k) Clearance for SCARLET® AC-Ti Anterior Cervical Cage

The SCARLET® AC-Ti cervical cage utilizes Spineart's proprietary Ti-LIFE technology1. Ti-LIFE technology, a proprietary additive manufacturing process, has a porous structure that closely mimics the trabecular bone structure. The SCARLET® AC-Ti cervical cage utilizes Spineart's proprietary Ti-LIFE technology 1. Ti-LIFE technology, a proprietary additive manufacturing process, has a porous structure that closely mimics the trabecular bone structure. "This approval underscores our…
PR Newswire
28/05/2024

Binge Eating Disorder Market to Accelerate Substantially During the Study Period…

Key Takeaways from the Binge Eating Disorder Market Report Key Takeaways from the Binge Eating Disorder Market Report Discover which therapies are expected to grab the major binge eating disorder market share @Binge Eating Disorder Market Report Binge Eating Disorder Overview Binge eating disorder is a serious mental health condition characterized by recurrent episodes of consuming large quantities of food in a short period while feeling a loss of control over eating behavior...
PR Newswire
28/05/2024

Robotic Radiotherapy Market Worth USD 2.9 Billion by 2031 at 12.0% CAGR- Latest…

Request for Free Sample Report: https://www.insightaceanalytic.com/request-sample/2501 Request for Free Sample Report: https://www.insightaceanalytic.com/request-sample/2501 Robotic radiotherapy is an advanced method of delivering radiation treatment to cancer patients using highly sophisticated robotic technology. This technique allows extremely precise targeting of radiation doses to the tumor, minimizing damage to the surrounding healthy tissues. Robotic radiotherapy is especially...
PR Newswire
28/05/2024

High-performance Computing for Life Sciences Market Expected to Grow at a CAGR…

Get Free PDF Report Brochure: https://www.insightaceanalytic.com/report/high-performance-computing-for-life-sciences-market/2497 Get Free PDF Report Brochure: https://www.insightaceanalytic.com/report/high-performance-computing-for-life-sciences-market/2497 The high-performance computing (HPC) sector has emerged as a vital component in advancing life sciences research and applications, offering unprecedented computational power and capabilities to tackle complex biological and medical...
PR Newswire
28/05/2024

TVM Capital Healthcare Announces the Closing of its Saudi Arabia-Focused TVM…

TVM Capital Healthcare identifies unmet healthcare needs and invests in entrepreneurial companies that create lasting impact in their local communities while delivering strong returns to investors. The firm has built a solid reputation as the first international fund manager investing in and operating major healthcare companies in the Kingdom. It also invests in healthcare growth deals in Europe and the U.S. to support these companies' expansion plans for Saudi Arabia and the wider GCC. With…
PR Newswire
28/05/2024

Tattoo Removal Market to Reach $4.0 Billion, Globally, by 2035 at 19.1% CAGR…

Request Sample of the Report on Tattoo Removal Market Forecast 2035- https://www.alliedmarketresearch.com/request-sample/3537 Request Sample of the Report on Tattoo Removal Market Forecast 2035-https://www.alliedmarketresearch.com/request-sample/3537 Prime determinants of growth Growing advancements in tattoo removal technologies and presence of key players are the factors that drive the growth of the global tattoo removal market. However, high cost of tattoo removal procedures is...
PR Newswire
28/05/2024

Resolution Therapeutics to Participate in the Jefferies Global Healthcare…

View original content:https://www.prnewswire.co.uk/news-releases/resolution-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-302155382.html View original content: https://www.prnewswire.co.uk/news-releases/resolution-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-302155382.html
PR Newswire
28/05/2024

Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in…

This statement is made by the Board of Directors (the "Board") of Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") pursuant to section II.19 of the Nasdaq Stockholm takeover rules ("Section II.19") and Regulation 14D under the Securities Exchange Act of 1934, as amended (together with Section II.19, the "Takeover Rules"). This statement is made by the Board of Directors (the " Board ") of Calliditas Therapeutics AB…
PR Newswire
28/05/2024

Lifespin GmbH and Acıbadem Forge a Groundbreaking Metabolomics Partnership to…

Transformative Healthcare Across Continents Transformative Healthcare Across Continents The partnership's mission extends beyond improving patient care across Eurasia; it ambitiously targets expansion intoAfricaand the Arabian Peninsula, withIstanbulpositioned as the central hub. Moreover, this strategic alignment promises to bridge continents with top-tier healthcare solutions, enhancing access to advanced healthcare diagnostics. "We are thrilled to collaborate with Acıbadem...
PR Newswire
28/05/2024

Description of the regulatory framework of the share repurchase program proposed…

PARIS, FRANCE, 28 May 2024 - In accordance with the provisions of Article L.22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014, the Delegated Regulation No 2016/1052 of 8 March 2016, and the General Regulation of the FrenchAutorité des Marchés Financiers(AMF), the present description aims to describe the objectives and characteristics of the repurchase by the Company of its own shares,...
Nasdaq GlobeNewswire
28/05/2024
Altri  Comunicati